کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2773069 1567898 2015 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis
ترجمه فارسی عنوان
درمان دراز مدت وارفارین و بیومارکرها برای استئوپروز و آترواسکلروز
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی بیوشیمی بالینی
چکیده انگلیسی


• Stroke prevention by warfarin has been an integral part in the management of atrial fibrillation.
• Warfarin prevents the activation of vitamin K-dependent proteins, MGP and Gas-6.
• Long-term warfarin therapy increases the serum levels of ucOC and RANKL.
• Long-term warfarin therapy is associated with vascular endothelial dysfunction.

BackgroundStroke prevention by warfarin, a vitamin K antagonist, has been an integral part in the management of atrial fibrillation. Vitamin K-dependent matrix Gla protein (MGP) has been known as a potent inhibitor of arterial calcification and osteoporosis. Therefore, we hypothesized that warfarin therapy affects bone mineral metabolism, vascular calcification, and vascular endothelial dysfunction.MethodsWe studied 42 atrial fibrillation patients at high-risk for atherosclerosis having one or more coronary risk factors. Twenty-four patients had been treated with warfarin for at least 12 months (WF group), and 18 patients without warfarin (non-WF group). Bone alkaline phosphatase (BAP) and under carboxylated osteocalcin (ucOC) and receptor activator of nuclear factor-kappa B ligand (RANKL) were measured as bone metabolism markers. Reactive hyperemia-peripheral arterial tonometry (RH-PAT) index measured by Endo-PAT2000 was used as an indicator of vascular endothelial function.ResultsThere were no significant differences in patient background characteristics and other clinical indicators between the two groups. In WF group, the ucOC levels were significantly higher than those in the non-WF group (10.3 ± 0.8 vs. 3.4 ± 0.9 ng/mL; P < 0.01), similarly, the RANKL levels in the WF group were higher than those in the non-WF group (0.60 ± 0.06 vs. 0.37 ± 0.05 ng/mL; P = 0.007). Moreover, RH-PAT index was significantly lower in the WF group compared to those in the non-WF group (1.48 ± 0.11 vs. 1.88 ± 0.12; P = 0.017).ConclusionsLong-term warfarin therapy may be associated with bone mineral loss and vascular calcification in 60–80 year old hypertensive patients.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: BBA Clinical - Volume 4, December 2015, Pages 76–80
نویسندگان
, , , , , , , , , , ,